Uroplasty Company Profile - Aug 06, 2011

Document Sample
Uroplasty Company Profile - Aug 06, 2011 Powered By Docstoc
					Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Uroplasty, Inc.
                                                                                          440 Wheelers Farms Road
                                                                                          Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:DCNN                                 Key Data

   Uroplasty, Inc. is a medical device company that develops, manufactures and              Ticker:
   markets products for the treatment of voiding dysfunctions. The Company's primary        UPI
   focus is on two products: the Urgent PC system and Macroplastique. The Urgent PC
   system is a United States Food and Drug Administration (FDA)-approved minimally          2011 Sales:
   invasive, office-based neuromodulation therapy for the treatment of urinary urgency,
                                                                                            13,787,032
   urinary frequency and urge incontinence that are symptoms often associated with
   overactive bladder (OAB). Macroplastique is a urethral bulking agent for the
   treatment of adult female stress urinary incontinence primarily due to intrinsic         Major Industry:
   sphincter deficiency (ISD). Outside of the United States, the Company's Urgent PC is     Drugs, Cosmetics & Health
   also approved for treatment of fecal incontinence, and Macroplastique is also            Care
   approved for treatment of male stress incontinence and vesicoureteral reflux.
                       Stock Chart                                    Officers              Sub Industry:
                                                                      Chairman              Medical, Surgical & Dental
                                                                  R. Patrick Maxwell        Suppliers

                                                         President & Chief Executive        Country:
                                                               David B. Kaysen              United States

                                                              Chief Operating Officer &     Currency:
                                                                     Secretary              U.S. Dollars
                                                                Susan Hartjes Holman
                                                                                       Fiscal Year Ends:
                                                            Vice President, Chief
                                                                                       March
                                                        Financial Officer, & Treasurer
                                                               Mahedi A. Jiwani
                                                                                       Employees
                                                                                       88
                                                             Managing Director
                                                                  Arie J. Koole
                                                                                       Exchanges:
                                                                                       NAS

                                                                                            Share Type:
             Stock Price (7/29/2011): 6.81                                                  Common
               Recent stock performance
                  1 Week      -16.1%
                                                                         
				
DOCUMENT INFO
Description: Uroplasty, Inc. is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions. The Company's primary focus is on two products: the Urgent PC system and Macroplastique. The Urgent PC system is a United States Food and Drug Administration (FDA)-approved minimally invasive, office-based neuromodulation therapy for the treatment of urinary urgency, urinary frequency and urge incontinence that are symptoms often associated with overactive bladder (OAB). Macroplastique is a urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (ISD). Outside of the United States, the Company's Urgent PC is also approved for treatment of fecal incontinence, and Macroplastique is also approved for treatment of male stress incontinence and vesicoureteral reflux.
BUY THIS DOCUMENT NOW PRICE: $24.95 100% MONEY BACK GUARANTEED
PARTNER Wright Investors' Service
Wright Investors' Service is an internationally recognized investment management and financial advisory firm headquartered in Milford, Connecticut. For more than 40 years, Wright has used well-defined and sophisticated investment strategies to help institutions, plan sponsors, bank trust departments, trust companies and individual investors achieve their financial objectives through a sensible approach to managing assets that balances risk and return.